4.6 Article

Ras and Rap1: A tale of two GTPases

Journal

SEMINARS IN CANCER BIOLOGY
Volume 54, Issue -, Pages 29-39

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2018.03.005

Keywords

Ras; Rap1; Integrins; Cell-adhesion; EMT; Metabolism; Rap1Gap; ERK/MAPK; FTI

Categories

Funding

  1. Neurofibromatosis Therapeutic Acceleration Program
  2. Wayne State University Office of the Vice-President for Research
  3. Department of Pharmacology Research Stimulation Fund
  4. [R01 CA131990]
  5. [T32 CA009531]
  6. [F31 CA213807]
  7. [R21 CA175931]
  8. [U54 CA193489]

Ask authors/readers for more resources

Ras oncoproteins play pivotal roles in both the development and maintenance of many tumor types. Unfortunately, these proteins are difficult to directly target using traditional pharmacological strategies, in part due to their lack of obvious binding pockets or allosteric sites. This obstacle has driven a considerable amount of research into pursuing alternative ways to effectively inhibit Ras, examples of which include inducing mislocalization to prevent Ras maturation and inactivating downstream proteins in Ras-driven signaling pathways. Ras proteins are archetypes of a superfamily of small GTPases that play specific roles in the regulation of many cellular processes, including vesicle trafficking, nuclear transport, cytoskeletal rearrangement, and cell cycle progression. Several other superfamily members have also been linked to the control of normal and cancer cell growth and survival. For example, Rap1 has high sequence similarity to Ras, has overlapping binding partners, and has been demonstrated to both oppose and mimic Ras-driven cancer phenotypes. Rap1 plays an important role in cell adhesion and integrin function in a variety of cell types. Mechanistically, Ras and Rap1 cooperate to initiate and sustain ERK signaling, which is activated in many malignancies and is the target of successful therapeutics. Here we review the role activated Rap1 in ERK signaling and other downstream pathways to promote invasion and cell migration and metastasis in various cancer types.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Chemistry, Medicinal

How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization

Ethan J. Brock, Kyungmin Ji, John J. Reiners, Raymond R. Mattingly

MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)

Review Oncology

In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ

Ethan J. Brock, Kyungmin Ji, Seema Shah, Raymond R. Mattingly, Bonnie F. Sloane

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2019)

Article Oncology

Downregulation of Rapt Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation

Seema Shah, Ethan J. Brock, Ryan M. Jackson, Kyungmin Ji, Julie L. Boerner, Bonnie F. Sloane, Raymond R. Mattingly

NEOPLASIA (2018)

Article Multidisciplinary Sciences

Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma

Ethan J. Brock, Ryan M. Jackson, Julie L. Boerner, Quanwen Li, Meredith A. Tennis, Bonnie F. Sloane, Raymond R. Mattingly

Summary: Research on breast ductal carcinoma in situ (DCIS) suggests that Sprouty4 plays a crucial role in controlling ERK/MAPK signaling, thereby limiting the progression of these lesions towards invasive ductal carcinoma (IDC).

PLOS ONE (2021)

No Data Available